Amicus Therapeutics, Inc. Earnings

Amicus Therapeutics, Inc.’s revenue jumped 30.09% since last year same period to $149.71Mn in the Q4 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 5.79% jump in its revenue since last 3-months.

Amicus Therapeutics, Inc.’s net profit jumped 143.55% since last year same period to $14.74Mn in the Q4 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 319.04% jump in its net profits since last 3-months.

Amicus Therapeutics, Inc.’s net profit margin jumped 133.48% since last year same period to 9.85% in the Q4 2024. On a quarterly growth basis, Amicus Therapeutics, Inc. has generated 307.06% jump in its net profit margins since last 3-months.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.07 - a -176.84% fall from last quarter’s estimates.

Amicus Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.07.

Amicus Therapeutics, Inc.’s earning per share (EPS) jumped 181.82% since last year same period to 0.09 in the Q4 2024. This indicates that the Amicus Therapeutics, Inc. has generated 181.82% annual rate of jump in its earning per share (EPS) in the last 4 quarters.